Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3

Topics Sun Pharma

Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.
Sun Pharma's new molecule for diabetes treatment is likely to get into phase 1 clinical trials in the third quarter of this fiscal after it showed promise in animal trials, the company said on Wednesday.

The stock prices, however, dropped by 3.3 per cent on the BSE at the end of day's trade.

The new chemical entity (NCE) named GL0034 is a long acting molecule used to treat patients with type 2 diabetes. These are called long acting GLP -1R agonists.

Dilip Shanghvi, Managing Director, Sun Pharma said, “We are excited by the robust pre-clinical data for GL0034 and believe that it has significant potential. We look forward to validating this data in human clinical trials.” Sun Pharma is planning to initiate Phase-1 clinical trials for GL0034 by Q3FY21.

The pre-clinical data for GL0034 was recently presented at the American Diabetes Association (ADA) Virtual 80th Scientific Sessions. GL0034 has been developed internally by Sun Pharma’s High Impact Innovations – Sustainable Health Solutions (HISHS) Discovery Team.

In the animal trials, the performance of the NCE was assessed in mice. The NCE demonstrated outcomes of various diabetes parameters like glucose reduction, decrease in HbA1c (an important market for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels, the company claimed.

Yet another important feature in diabetes treatment is weight management. GL0034 induced a larger body weight reduction.


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel